Register for our free email digests:
Latest From Harvard Bioscience Inc.
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
In a deal worth over $1 billion, Depomed got US rights to Janssen's pain drug Nucynta; Roche bought the majority stake in Foundation Medicine. FOPOs drove a large part of biopharma financing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.
BMS teamed up with F-start Alpha and also received an option to acquire; BD bought hospital care systems provider CareFusion for $11.8 billion. IPOs made up nearly a quarter of total dollars in both biopharma and device financing.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Laboratory Testing Services
- Anatomical Pathology
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- NeoGenomics Inc.
- Senior Management
Douglas M VanOort, Chmn. & CEO
George Cardoza, CFO
Maher Albitar, MD, SVP, Dir., R&D & CMO
- Contact Info
Phone: (239) 768-0600
12701 Commonwealth Dr.
Ft. Myers, FL 33913
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.